Apolipoprotein A-I from human plasma

Apolipoprotein A-I from human plasma has been used to induce cholesterol efflux in nitrobenzoxadiazole (NBD)-cholesterol loaded cells. It has also been used to detect IgG anti-apoA-1 antibodies using enzyme linked immunosorbent assay (ELISA).

Major protein components in high density lipoprotein (HDL)

Activates lecithin-cholesterol acyltransferase (LCAT), which is responsible for cholesterol esterification in plasma.

Apo-AI comprises ~70% of the protein moiety in HDL. It is a single polypeptide chain consisting of 245 amino acids with glutamic acid as the C-terminal residue and aspartic acid as the N-terminal residue. The molecular mass is reported to be 28.3 kDa. The protein is made up of one major isoform (pI 5.6) and two minor isoforms (pI 5.53 and 5.46). Apo-AI shows a high content of α-helix structure. The amphipathic regions in the α-helix structure seem to be responsible for lipid binding capacity. In aqueous solution, Apo-AI shows self-association with minor conformation change. Apo-AI activates lecithin-cholesterol (LCAT) acyltransferase, which is responsible for cholesterol esterification in plasma.

Apo-AI levels in normal plasma are 90-130 mg/dl. Apo-AI levels may be inversely related to the risk of coronary disease.

Solution in 10 mM ammonium bicarbonate

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.